Prab at 12:52, 18 March 2025

2025-03-18T12:52:58Z

← Older revision		Revision as of 12:52, 18 March 2025
Line 39:		Line 39:
	{{dictionary-stub1}}		{{dictionary-stub1}}
	{{No image}}		{{No image}}
	~~__NOINDEX__~~

Prab: CSV import

2025-03-17T15:22:26Z

CSV import

← Older revision		Revision as of 15:22, 17 March 2025
Line 39:		Line 39:
	{{dictionary-stub1}}		{{dictionary-stub1}}
	{{No image}}		{{No image}}
			__NOINDEX__

Prab: CSV import

2025-02-10T19:32:50Z

CSV import

← Older revision		Revision as of 19:32, 10 February 2025
Line 38:		Line 38:
	{{stub}}		{{stub}}
	{{dictionary-stub1}}		{{dictionary-stub1}}
			{{No image}}

Prab: CSV import

2024-02-24T05:33:18Z

CSV import

New page

'''Interim analysis''' is a statistical procedure that is used in [[clinical trials]] to analyze the data before the trial is completed. This is done to determine if the trial should be stopped early due to safety concerns, efficacy, or futility.

== Overview ==

In [[clinical research]], interim analysis is a planned analysis of data collected from participants before the study is completed. The main purpose of interim analysis is to ensure the safety of the participants and to assess the progress of the trial. It can also be used to determine if the trial should be stopped early due to safety concerns, efficacy, or futility.

== Purpose ==

The primary purpose of interim analysis is to protect the [[patient]]'s safety. If the interim analysis shows that the treatment is not effective or is causing harm, the trial can be stopped early to prevent further harm to the participants.

Interim analysis can also be used to determine if the trial is likely to show a significant result if it continues to the end. If the interim analysis shows that the trial is unlikely to show a significant result, the trial can be stopped early to save resources.

== Procedure ==

Interim analysis is usually performed by a [[Data Monitoring Committee]] (DMC) or a similar independent group. The DMC reviews the data collected from the trial and makes recommendations based on their analysis. The DMC can recommend that the trial continue as planned, be modified, or be stopped early.

== Limitations ==

While interim analysis can provide valuable information, it also has some limitations. One limitation is that it can increase the chance of a [[Type I error]], which is the incorrect rejection of a true null hypothesis. To control for this, statistical methods such as the [[O'Brien-Fleming method]] or the [[Pocock method]] can be used.

Another limitation is that interim analysis can lead to bias if the results are shared with the trial investigators or participants. To prevent this, the results of the interim analysis are usually kept confidential and are only shared with the DMC.

== See also ==

* [[Clinical trial]]
* [[Data Monitoring Committee]]
* [[O'Brien-Fleming method]]
* [[Pocock method]]

== References ==

<references />

[[Category:Medical research]]
[[Category:Clinical trials]]
[[Category:Statistical methods]]

{{stub}}
{{dictionary-stub1}}

Interim analysis - Revision history

Prab at 12:52, 18 March 2025

Prab: CSV import

Prab: CSV import

Prab: CSV import